Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Enabling a new era in minimally invasive obesity treatment across Europe
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Subscribe To Our Newsletter & Stay Updated
